Analysts expect that Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) will post earnings per share of ($0.37) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Aeglea Bio Therapeutics’ earnings. Aeglea Bio Therapeutics reported earnings of ($0.47) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 21.3%. The firm is scheduled to issue its next earnings results on Wednesday, August 8th.
According to Zacks, analysts expect that Aeglea Bio Therapeutics will report full year earnings of ($1.67) per share for the current year. For the next fiscal year, analysts forecast that the firm will report earnings of ($3.57) per share. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Aeglea Bio Therapeutics.
Aeglea Bio Therapeutics (NASDAQ:AGLE) last released its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.05). Aeglea Bio Therapeutics had a negative net margin of 507.82% and a negative return on equity of 54.83%. The company had revenue of $1.51 million during the quarter.
Several equities research analysts have issued reports on the company. BMO Capital Markets assumed coverage on Aeglea Bio Therapeutics in a report on Thursday, June 14th. They set an “outperform” rating and a $21.00 price target for the company. ValuEngine raised Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, June 1st. Zacks Investment Research raised Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a report on Tuesday, May 15th. Evercore ISI assumed coverage on Aeglea Bio Therapeutics in a report on Tuesday, April 24th. They set an “outperform” rating and a $37.00 price target for the company. Finally, Needham & Company LLC raised their price target on Aeglea Bio Therapeutics to $20.00 and gave the company a “buy” rating in a report on Friday, April 13th. Five investment analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average target price of $22.50.
In other Aeglea Bio Therapeutics news, major shareholder Bioventures Ltd Novartis sold 73,955 shares of the firm’s stock in a transaction on Thursday, May 10th. The stock was sold at an average price of $10.12, for a total transaction of $748,424.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 27.00% of the company’s stock.
A number of hedge funds have recently bought and sold shares of AGLE. Millennium Management LLC grew its holdings in Aeglea Bio Therapeutics by 436.5% during the first quarter. Millennium Management LLC now owns 74,190 shares of the biotechnology company’s stock worth $736,000 after buying an additional 60,361 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Aeglea Bio Therapeutics by 153.9% during the first quarter. Dimensional Fund Advisors LP now owns 91,848 shares of the biotechnology company’s stock worth $911,000 after buying an additional 55,679 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Aeglea Bio Therapeutics by 737.2% during the first quarter. JPMorgan Chase & Co. now owns 50,652 shares of the biotechnology company’s stock worth $502,000 after buying an additional 44,602 shares in the last quarter. UBS Group AG grew its holdings in Aeglea Bio Therapeutics by 1,752.6% during the first quarter. UBS Group AG now owns 24,565 shares of the biotechnology company’s stock worth $244,000 after buying an additional 23,239 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Aeglea Bio Therapeutics by 150.8% during the fourth quarter. Renaissance Technologies LLC now owns 32,100 shares of the biotechnology company’s stock worth $174,000 after buying an additional 19,300 shares in the last quarter. Hedge funds and other institutional investors own 38.79% of the company’s stock.
Aeglea Bio Therapeutics traded down $0.05, hitting $10.17, during mid-day trading on Friday, MarketBeat reports. 140,692 shares of the company’s stock traded hands, compared to its average volume of 342,811. Aeglea Bio Therapeutics has a fifty-two week low of $2.81 and a fifty-two week high of $12.00. The company has a market capitalization of $223.40 million, a price-to-earnings ratio of -5.65 and a beta of 0.07.
About Aeglea Bio Therapeutics
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.